

## Bayer divests generics business in Spain

### Focus on business with innovative medicines

---

**Leverkusen** – The Spanish generics company Bayvit S.A., headquartered in Barcelona, is to be acquired by STADA Arzneimittel AG of Bad Vilbel, Germany. The divestors are the Bayer Group and privately owned Vita Invest S.A., Barcelona, each of whom hold a 50 percent interest in Bayvit.

Bayvit S.A. is a sales and marketing company with no manufacturing and product development activities of its own. The company has some 90 employees, more than 70 of whom work on the sales force. Bayvit's product range encompasses 27 generics for various therapeutic groups. The company has been operating since 1997. Its sales grew by 50 percent in 2001 to EUR 20 million. This makes Bayvit the second largest generics supplier in Spain.

"The divestiture of our Spanish generics activities strengthens Bayer Pharma's overall strategy of concentrating on business with innovative medicines," said Dr. Wolfgang Plischke, General Manager of the Pharmaceuticals Business Group of Bayer AG. "Generics are no longer a core activity of Bayer in view of our corporate strategy for the future."

Bayer recently sold its French generics business to Teva Pharmaceutical Industries Ltd. of Israel.

Leverkusen, 2002-04-17

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

